Evidence map›Paper›PMID 36940916›Full record

ArticleAntiviral research2023

SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.

Rubens Prince Dos Santos Alves, Ying-Ting Wang, Zbigniew Mikulski, Sara McArdle, Norazizah Shafee, Kristen M Valentine, Robyn Miller, Shailendra Kumar Verma, Fernanda Ana Sosa Batiz, Erin Maule and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Rubens Prince Dos Santos AlvesCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Ying-Ting WangCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Zbigniew MikulskiMicroscopy and Histology Core Facility, La Jolla Institute for Immunology, La Jolla, CA, USA.
Sara McArdleMicroscopy and Histology Core Facility, La Jolla Institute for Immunology, La Jolla, CA, USA.
Norazizah ShafeeCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kristen M ValentineCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Robyn MillerCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Shailendra Kumar VermaCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Fernanda Ana Sosa BatizCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Erin MauleCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Michael N NguyenCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Julia TimisCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Colin MannCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Michelle ZandonattiCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Suzie AlarconSequencing Core Facility, La Jolla Institute for Immunology, La Jolla, CA, USA.
Jenny RoweCharles River Laboratories Research Models and Services Inc., Wilmington, MA, USA.
Mitchell KronenbergDivision of Developmental Immunology, La Jolla Institute for Immunology, La Jolla, CA, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, 92037, USA.
Kathryn HastieCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Stephen FestinCharles River Laboratories Research Models and Services Inc., Wilmington, MA, USA.
Kenneth KimHistopathology Core Facility, La Jolla Institute for Immunology, La Jolla, CA, USA. Electronic address: kenneth@lji.org.
Sujan ShrestaCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA. Electronic address: sujan@lji.org.
La Jolla Institute for Immunology · USCharles River Laboratories (United States) · US

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
NIAID NIH HHS T32 AI007036NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

Although severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initially infects the respiratory tract, it also directly or indirectly affects other organs, including the brain. However, little is known about the relative neurotropism of SARS-CoV-2 variants of concern (VOCs), including Omicron (B.1.1.529), which emerged in November 2021 and has remained the dominant pathogenic lineage since then. To address this gap, we examined the relative ability of Omicron, Beta (B.1.351), and Delta (B.1.617.2) to infect the brain in the context of a functional human immune system by using human angiotensin-converting enzyme 2 (hACE2) knock-in triple-immunodeficient NGC mice with or without reconstitution with human CD34

Indexed as

COVID-19SARS-CoV-2AnimalsBrainDisease Models, AnimalHumansMiceBrainCOVID-19Human ACE2Human CD34 immune cellsMouse modelNCGNeurotropismOmicronSARS-CoV-2T cell

Identifiers

PMID36940916
PMCPMC10027296
OpenAlexW4327920437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.